Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancer Journal Article


Authors: Dizon, D. S.; Hensley, M. L.; Poynor, E. A.; Sabbatini, P.; Aghajanian, C.; Hummer, A.; Venkatraman, E.; Spriggs, D. R.
Article Title: Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancer
Abstract: Purpose: The majority of patients with epithelial ovarian cancer (EOC) who achieve a complete remission with front-line chemotherapy develop recurrent disease. Carboplatin and paclitaxel are used for patients with platinum-sensitive recurrent disease, although there is little information regarding the response and survival in unselected patients treated with this strategy. We sought to determine the outcomes for patients with EOC treated with carboplatin and paclitaxel at the time of first recurrence. In addition, we sought to define a new paradigm for disease transition in patients with EOC. Patients and Methods: Eighty-nine patients were identified who had a complete response to front-line platinum-based chemotherapy for EOC, relapsed 6 months after completion of front-line chemotherapy, and were treated with carboplatin and paclitaxel as second-line therapy. Results: Eighty-four cases were available for analysis of survival end points, and 66 were assessable for response. The median follow-up was 27 months. The overall response rate was 70%. The median progression-free interval for the cohort was 13 months (95% confidence interval [CI], 10.7 to 13.8 months). The 3-year survival rate was 72% (95% CI, 59.4 to 86.1%). Toxicity was limited, and no deaths from treatment were observed. Using this data, it is possible to construct a disease states model of EOC, which provides risk estimates for transitions between clinically distinct categories. Conclusion: Re-treatment with carboplatin and paclitaxel is effective as initial therapy in recurrent EOC. This should form the basis of a randomized trial to determine the best agents for initial treatment of relapse from EOC in potentially platinum-sensitive patients. © 2002 by American Society of Clinical Oncology.
Keywords: adult; cancer survival; controlled study; treatment outcome; aged; middle aged; survival rate; retrospective studies; major clinical study; fatigue; neutropenia; cancer recurrence; antineoplastic agents; paclitaxel; follow up; follow-up studies; ovarian neoplasms; demography; carboplatin; mucosa inflammation; nausea; vomiting; antineoplastic agents, phytogenic; cohort analysis; retrospective study; cancer model; models, theoretical; pneumonia; cancer regression; urinary tract infection; ovary carcinoma; platinum; anaphylaxis; allergic reaction; small intestine obstruction; humans; human; female; priority journal; article
Journal Title: Journal of Clinical Oncology
Volume: 20
Issue: 5
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2002-03-01
Start Page: 1238
End Page: 1247
Language: English
DOI: 10.1200/jco.20.5.1238
PUBMED: 11870166
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 14 November 2014 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Venkatraman Ennapadam Seshan
    285 Seshan
  2. Amanda J Hummer
    60 Hummer
  3. Elizabeth Poynor
    30 Poynor
  4. Don S Dizon
    21 Dizon
  5. Paul J Sabbatini
    199 Sabbatini
  6. Martee L Hensley
    220 Hensley
  7. David R Spriggs
    312 Spriggs